drugset / Trial / NCT05264584
Renoprotective Effect of Febuxostat on Contrast Induced Acute Kidney Injury in Chronic Kidney Disease Patients Stage 3
RandomizedParallel-groupOpen-labelPrevention
Summary
This study will determine the renoprotective effect of febuxostat in prevention of contrast induced acute kidney injury in chronic kidney disease patients Stage 3 undergoing percutaneous coronary intervention.
Timeline
- Start
- 2020-12-01
- Primary completion
- 2021-09-01
- Completion
- 2022-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Febuxostat | Small molecule | 80 mg | — |
| Background | N-acetylcysteine | Small molecule | 600 mg | Oral |
| Background | N-acetylcysteine | Small molecule | 1200 mg | Oral |
| Background | sodium chloride | Unknown | — | Intravenous |